Menu
Back to Journals » Drug, Healthcare and Patient Safety » Volume 5
Clinical utility and tolerability of linagliptin in diabetic patients
Authors Maxwell L, McFarland MS
Received 2 November 2012
Accepted for publication 27 November 2012
Published 22 March 2013 Volume 2013:5 Pages 67—78
DOI https://doi.org/10.2147/DHPS.S28823
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Lauralee Gordon Maxwell,1 M Shawn McFarland1,2
1Department of Veterans Affairs, TN Valley Healthcare System, Murfreesboro, 2The University of Tennessee Department of Clinical Pharmacy, Memphis, TN, USA
Background: The purpose of this paper is to review the efficacy, safety, and tolerability of linagliptin in the management of hyperglycemia in adults with type 2 diabetes mellitus.
Methods: A Medline search was performed using the keywords “linagliptin” and “type 2 diabetes” for articles published September 2010 through July 2012. The literature search was limited by the following criteria: articles' publication in the English language, clinical trials, randomized controlled trials, and research conducted in humans.
Results: A review of the data for linagliptin in the treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic therapies suggests clinical efficacy in terms of reductions in glycosylated hemoglobin, fasting plasma glucose, and postprandial glucose. Most adverse events with linagliptin are considered to be mild to moderate in nature. Although linagliptin therapy may offer a low risk of hypoglycemia, the risk increases when it is used in combination with insulin secretagogues. Linagliptin can generally be considered weight neutral, but a weight increase was observed when linagliptin was used in combination with a thiazolidinedione.
Conclusion: Linagliptin is a once-daily oral medication used for the treatment of type 2 diabetes. The use of linagliptin as monotherapy or in combination with metformin, sulfonylureas, or pioglitazone led to improvement in glycemic control and was well tolerated by most patients.
Keywords: type 2 diabetes, linagliptin, dipeptidyl peptidase-4 inhibitor
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.